Period of time： 2014年2期
Publisher： Springer Publishing Company
Founded in： 1983
Total resources： 32
ISSN： 0167-6997
Subject： R9 Pharmacy
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Investigational New Drugs,volume 25,issue 2
Menu
By Jin Jing,Sun Hua,Wei Huailing,Liu Gengtao in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.
Access to resources
Recommend
By Pourpak Alan,Dorr Robert,Meyers Ross,Powell Marianne,Stratton Steven in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.By Brooks Tracy,O’Loughlin Kieran,Minderman Hans,Bundy Brian,Ford Laurie,Vredenburg Michael,Bernacki Ralph,Priebe Waldemar,Baer Maria in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.By Dawson S.,Michael M.,Biagi J.,Foo K.,Jefford M.,Ngan S.,Leong T.,Hui A.,Milner A.,Thomas R.,Zalcberg J. in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.By Camacho Luis,Olson Jon,Tong William,Young Charles,Spriggs David,Malkin Mark in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients
By Flaig Thomas,Gustafson Daniel,Su Lih-Jen,Zirrolli Joseph,Crighton Frances,Harrison Gail,Pierson A.,Agarwal Rajesh,Glodé L. in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.A phase 1 trial of XK469: Toxicity profile of a selective topoisomerase IIβ inhibitor
By Alousi Amin,Boinpally Ramesh,Wiegand Richard,Parchment Ralph,Gadgeel Shirish,Heilbrun Lance,Wozniak Antionette,DeLuca Pamela,LoRusso Patricia in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.By Smylie Michael,Wong Ralph,Mihalcioiu Catalin,Lee Chris,Pouliot Jean-Francois in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules
By Burstein Harold,Overmoyer Beth,Gelman Rebecca,Silverman Paula,Savoie Jennifer,Clarke Kathryn,Dumadag Leda,Younger Jerry,Ivy Percy,Winer Eric in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
By Fury Matthew,Zahalsky Andrew,Wong Richard,Venkatraman Ennapadam,Lis Eric,Hann Lucy,Aliff Timothy,Gerald William,Fleisher Martin,Pfister David in (2007)
Investigational New Drugs,volume 25,issue 2 , Vol. 25, Iss. 2, 2007-04 , pp.
Previous
Next